Carisoprodol, marketed under the brand name Soma among others, is a prescription drug marketed since 1959. It is a centrally acting skeletal muscle relaxant of the carbamate class and produces all the effects associated with barbiturates. It is a prodrug and is both structurally and pharmacologically related to meprobamate. The major metabolic pathway of carisoprodol involves its conversion to meprobamate, a barbiturate-like drug.
Usual Adult Dose for Muscle Spasm
250 to 350 mg orally 3 times a day and at bedtime
Duration of therapy: Up to 2 to 3 weeks
-This drug should only be used for short periods (up to 2 or 3 weeks) as there is inadequate evidence of effectiveness for more prolonged use and acute, painful musculoskeletal conditions are generally of short duration.
Use: For the relief of discomfort associated with acute, painful musculoskeletal conditions
The usual dose of 350 mg is unlikely to engender prominent side effects other than somnolence, and mild to significant euphoria or dysphoria, but the euphoria is generally short lived. The medication is well tolerated and without adverse effects in the majority of patients for whom it is indicated. In some patients, however, and/or early in therapy, carisoprodol can have the full spectrum of sedative side effects and can impair the patient’s ability to operate a firearm, motor vehicles, and other machinery of various types, especially when taken with medications containing alcohol, in which case an alternative medication would be considered. The intensity of the side effects of carisoprodol tends to lessen as therapy continues, as is the case with many other drugs.